Freeze-dried group A and group C meningococcal polysaccharide conjugate vaccine is used to prevent diseases caused by Neisseria meningitidis group A or group C.
The vaccine is a capsular polysaccharide antigen obtained by fermentation and purification of group A meningococcal strain 2920 1 and group C meningococcal strain 29205 respectively, which is activated and derived by polysaccharide, and then combined with tetanus toxoid protein to form group A polysaccharide-protein conjugate and group C polysaccharide-protein conjugate, which are mixed according to a certain proportion, added with appropriate stabilizer and freeze-dried.